semaglutide and insulin combination FDA alerts health care providers, compounders patients of dosing errors associated with compounded injectable products Efficacy and safety of combination

The popularity of GLP-1 receptor agonists like Wegovy or Ozempic have led to a rise in medical expenses for employers through employer-backed health insurance

What impact do you think fully oral GLP-1 therapies could have on long-term patient adherence and accessibility

And other biotech news brought to you by The Readout newsletter

The answer, in our new @BMJMedicine, is more interesting than yes or no

Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier

PlexusDx offers compounded tirzepatide and semaglutide options tailored to your metabolic profile, starting at $249/month with no insurance required